New Interact features provide greater clarity to research, bid, and buy IAA, Inc. (NYSE: IAA), a leading global digital marketplace connecting vehicle buyers and sellers, announces the enhancement
Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and New Zealand
MUMBAI, India, March 2, 2021 /PRNewswire/ Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as Cipla today announced that its subsidiary, Cipla Gulf FZ LCC ( Cipla Gulf ) is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.
As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars leading products covering therapeutic categories across immunology, osteoporosis, oncology as well as ophthalmology.
The products are developed and manufactured by Alvotech and will be distributed by Cipla Gulf through Australia and New Zealand distribution networks. These innovative products recorded US$700 Mn in aggregate 2020 sales in Australia.
Cipla Gulf and Alvotech Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand
Gulf FZ LCC ( Cipla Gulf ), subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as Cipla and biopharmaceutical company Alvotech today announced that they are expanding their partnership for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.
As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of leading products covering therapeutic categories across immunology, osteoporosis, oncology as well as ophthalmology.
The products are developed and manufactured by Alvotech and will be distributed by Cipla Gulf through Australia and New Zealand distribution networks. These innovative products recorded US$700 Mn in aggregate 2020 sales in Australia.
Debiopharm Grants a Worldwide Exclusive License to Merck for the Development and Commercialization of Xevinapant
-
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care
-
A Phase II trial reported that xevinapant plus chemoradiotherapy reduced risk of death by 51% vs standard of care in this patient population; Phase III TrilynX study initiated in September 2020
-
Merck gains exclusive global development and commercialization rights; Debiopharm to receive €188 million upfront and up to €710 million in milestone, as well as royalty payments
WEST LAFAYETTE â Purdue University-affiliated startup NutraMaize is featured in a current national advertising campaign called âMake a Different Future.â
The campaign, presented by GoDaddy, champions real customers, such as NutraMaize CEO Evan Rocheford and the companyâs brand, Professor Torbertâs Orange Corn, driving change to âMake a Different Futureâ for themselves and for others. Following the challenges of 2020, the campaign states, âThe future isnât decided yet. Itâs still ours to win.â
âWe are so excited to be a part of spreading this message of hope for the future. As a company, we were founded on the belief that a better future is possible,â Rocheford said. âWe are on a mission to improve the nutritional quality of common foods people eat every day, so to have a platform like this to tell our story is just incredible.â